A clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio’s main focus is on its HCV NS5A inhibitor program, currently undergoing clinical studies and is well positioned to compete in the growing HCV therapy market.